RecruitingPhase 3NCT05378399

SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder

SmartSteps: A Context-Aware, Pre-Exposure Prophylaxis Adherence Intervention for Individuals With Substance Use Disorder


Sponsor

Brigham and Women's Hospital

Enrollment

40 participants

Start Date

Dec 20, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This is a single-arm, observational study of HIV-negative MSM with substance use disorder. Those who meet pre-screening criteria will attend a Screening Visit (Visit 1), where the informed consent process will be conducted and study eligibility will be confirmed. Eligible participants will attend three additional visits over the course of the study - the Enrollment Visit (Visit 2), Month 1 Visit (Visit 3), and Month 2 Visit (Visit 4). Participants will take one PrEP digital pill per day, for 60 days total, while using the digital pill system (DPS) and Beiwe, a digital phenotyping app. On nonadherent days, participants will receive brief surveys prompting them to report the reasons for their missed dose, as well as their engagement in substance use and sexual activity. Timeline followback will be conducted at the Month 1 and Month 2 Visits to understand the context of any nonadherence. Qualitative user experience exit interviews and dried blood spots (DBS) will be conducted at the Month 2 Visit.


Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria8

  • Age 18 or older
  • Cisgender male
  • Has sex with men
  • HIV negative
  • On PrEP or initiating PrEP (including switching from 2-1-1 or "on-demand" PrEP dosing to once-daily dosing)
  • Moderate risk score on ASSIST substance use screener (11-26 for alcohol, 4-26 for all other substances) or higher
  • Qualifying laboratory testing for PrEP: Cr clearance in past 3 months, HBV vaccination, liver function tests
  • Owns a smartphone with Android or iOS

Exclusion Criteria7

  • Does not speak English
  • History of Crohn's disease or ulcerative colitis
  • History of gastric bypass or bowel stricture
  • History of GI malignancy or radiation to abdomen
  • Allergy to gelatin, silver, or zinc (components of digital pill)
  • Allergy to PrEP
  • Not willing to operate DPS or Beiwe app

Interventions

DRUGDescovy or Truvada

Descovy or Truvada prescribed with digital pills for PrEP

DEVICEID-Cap System

Digital pills overencapsulating Descovy or Truvada for PrEP

DEVICEBeiwe

Digital phenotyping app


Locations(1)

Fenway Health

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05378399


Related Trials